bioRxiv· Sample, J. W., Ozmert, E. H., Wilbanks, B. A., Carlson, D. M., Nishi, H., Abdelrahman, A. M., Jessen, E., Cai, M., Mun, D.-g., Kuipers, H., Splinter, A., Ticho, A. L., Werneburg, N. W., Pandey, A., Truty, M. J., Borad, M., Ilyas, S. I., Gores, G. J., Smoot, R. L. ·· 1 day agoPickScore67
ESCRT-dependent YAP degradation by AKT blockade overcomes adaptive resistance to RAS(ON) inhibition in pancreatobiliary cancer
In brief
A study finds that AKT inhibition degrades YAP protein through an ESCRT-dependent lysosomal pathway, thereby overcoming adaptive resistance to RAS(ON) inhibition in pancreatobiliary cancer.
Why it matters
The study identifies a non-canonical mechanism in which AKT regulates YAP degradation via the ESCRT-lysosome pathway, providing preclinical evidence for combining the approved drug capivasertib with a pan-RAS inhibitor to overcome resistance in pancreatobiliary cancer.
Source: bioRxiv